Sutro Biopharma (STRO) Stock Price, News & Analysis

Company Overview

Sutro Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development. The company’s lead programs target solid tumors and hematologic malignancies, with several assets designed to engage the immune system through both targeted delivery of cytotoxic payloads and enhancement of T-cell activity. In addition to advancing its own pipeline, Sutro has forged research and development collaborations with global pharmaceutical partners to apply its XpressCF™ platform across a range of therapeutic areas.

With operations anchored in the San Francisco Bay Area, Sutro Biopharma serves both domestic and international partners through collaborative agreements and licensing arrangements. The company’s scientific leadership brings together expertise in protein engineering, antibody biology, and translational medicine, positioning Sutro to address challenging molecular targets and streamline the path from discovery to clinical testing. As a publicly traded entity on the NASDAQ under the symbol STRO, Sutro continues to pursue innovative biologic therapies aimed at improving outcomes for patients with cancer and other immune-related diseases.

Key Stats

• Today's Range: $24.93 to $26.29
• 50-Day Range: $22.59 to $33.35
• 52-Week Range: $7.15 to $43.85
• Volume: 135,115 shs
• Average Volume: 250,865 shs
• Market Capitalization: $423.03 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $52.00
• Consensus Rating: Moderate Buy

Sutro Biopharma Stock Analysis - MarketRank™

Sutro Biopharma scored higher than 53% of companies evaluated by MarketBeat, and ranked 359th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Sutro Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 2 strong buy ratings, 9 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Sutro Biopharma has a consensus price target of $52.00, representing about 103.7% upside from its current price of $25.53.

Amount of Analyst Coverage

Sutro Biopharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Sutro Biopharma are expected to grow in the coming year, from ($9.06) to ($7.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sutro Biopharma is -2.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sutro Biopharma is -2.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.16% of the float of Sutro Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Sutro Biopharma has a short interest ratio ("days to cover") of 4.46.

Change versus previous month

Short interest in Sutro Biopharma has recently increased by 21.36%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sutro Biopharma does not currently pay a dividend.

Dividend Growth

Sutro Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sutro Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.80% of the stock of Sutro Biopharma is held by insiders.

Percentage Held by Institutions

96.99% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 8/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:STRO
• CIK: 1382101
• Web: www.sutrobio.com
• Phone: (650) 392-8412
• Fax: N/A
• Employees: 240
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Sutro Biopharma: $52.00
• High Price Target: $100.00
• Low Price Target: $27.00
• Potential Upside/Downside: +103.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.92
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($11.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$191.09 million
• Net Margins: -154.21%
• Pretax Margin: -154.32%
• Return on Equity: N/A
• Return on Assets: -69.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.12
• Quick Ratio: 3.12

Sales & Book Value

• Annual Sales: $102.48 million
• Price / Sales: 4.13
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($15.43) per share
• Price / Book: -1.65

Miscellaneous

• Outstanding Shares: 16,570,000
• Free Float: 16,272,000
• Market Cap: $423.03 million
• Optionable: Optionable
• Beta: 1.55